Previous research has indicated that caspase-4 is an upstream control of SSa-induced DNA damage and caspase 4 activations in HCC cells, as well as the concurrent activation of caspase-2 and caspase-8, which is a crucial phase in SSa-triggered apoptosis and leads to caspase-mediated apoptosis in HCC cells, suggesting that it may be a promising CRC therapeutic agent [167]. The gene discussed is CASP4; the disease is hepatocellular carcinoma.